je.st
news
Merck Acquires IOmet Pharma and Expands Immuno-Oncology Development Program
2016-01-11 22:08:00| Merck.com - Corporate News
Dateline City: KENILWORTH, N.J. Acquisition Grows Mercks Oncology Pre-Clinical Pipeline with Novel IDO1 and TDO Inhibitors KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that it has acquired IOmet, a privately-held UK-based drug discovery company focused on the development of innovative medicines for the treatment of cancer, with a particular emphasis on the fields of cancer immunotherapy and cancer metabolism. Language: English Contact: MerckMedia:Pamela Eisele, 267-305-3558Courtney Ronaldo, 908-236-1108orInvestors:Teri Loxam, 908-740-1986Justin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: development
program
pharma
expands
Category:Biotechnology and Pharmaceuticals